查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1654360

全球半固态剂量 CDMO 市场：市场规模、份额、趋势分析（按给药途径、产品、服务、最终用途和地区）、细分市场预测（2025-2030 年）

Semi-Solid Dosage CDMO Market Size, Share & Trends Analysis Report By Route of Administration (Topical, Transdermal), By Product, By Service, By End Use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 145 Pages | 商品交期: 2-10个工作天内

价格

半固态剂量 CDMO 市场的成长与趋势：

根据Grand View Research, Inc.的最新报告，全球半固态剂量CDMO市场规模预计到2030年将达到674亿美元，2025年至2030年期间的复合年增长率为11.90%。

全球半固态剂量 CDMO 市场规模的成长受到个人化医疗日益增长的趋势以及对创新药物输送系统日益增长的需求的推动。半固态製剂如乳膏、凝胶和软膏因易于涂抹、吸收迅速而更受患者青睐。此外，它在皮肤病治疗中也被广泛采用，以增加患者的治疗选择。根据美国皮肤病学会 2024 年 9 月发布的资料，痤疮是美国最常见的疾病，每年影响约 5,000 万人。此外，其中85％的年龄在12岁至24岁之间。因此，皮肤病发病率的不断上升导致对外用製剂开发的需求增加，从而推动对 CDMO 扩大其半固态製剂能力的需求。

此外，配方和製造流程的持续技术进步也推动了半固态剂型市场的发展。奈米技术和先进的乳化技术等创新正在提高半固态剂型的功效和稳定性。这些进步使 CDMO 能够生产符合严格监管要求的更高品质的产品，从而吸引更多客户。例如，乳化的发展提高了活性成分的生物利用度，使得半固态製剂能够更有效地用于治疗各种疾病，包括慢性疼痛和发炎疾病。

此外，慢性病盛行率不断上升加上人口老化也促进了半固态剂量 CDMO 市场的成长。随着越来越多的人寻求治疗关节炎、糖尿病和皮肤病等疾病，对有效半固态的需求预计在未来几年将会增长。这一趋势在老年护理中尤其明显，半固态製剂由于易于使用而更受青睐。因此，这些因素进一步促进了市场的成长。

半固态剂型 CDMO 市场：概览

  • 按产品划分，外用药物将占据市场主导地位，到 2024 年将占有 88.53% 的份额。这些配方对于局部治疗特别有效且是皮肤科应用的理想选择。
  • 根据给药途径，乳膏/乳液部分将在 2024 年占据半固态剂量 CDMO 行业的主导地位，份额为 42.49%。这些配方具有独特的优势，如易于使用、质地宜人、皮肤吸收性更强，从而促进了这一领域的成长。
  • 按服务划分，契约製造部门在 2024 年占据了最大的收入份额。製药公司越来越多地将製造流程委託给 CDMO，以便专注于研发等核心竞争力。
  • 根据最终用途，製药部门在 2024 年占据了最大的收益占有率。这是因为对创新治疗解决方案的需求不断增长，从而推动公司增加对开发新药的投资。
  • 2024 年北美占据市场主导地位，份额为 41.37%。市场扩张的动力源于该地区慢性病发病率的上升，刺激了对先进治疗解决方案的需求。

目录

第一章 分析方法及范围

第 2 章执行摘要

3. 半固态剂型 CDMO 市场：驱动因素、趋势与范围

  • 市场联动展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制分析
  • 半固态剂型 CDMO 市场：分析工具
    • 产业分析：波特五力分析
    • PESTEL 分析
    • COVID-19影响分析

第 4 章半固态剂量 CDMO 市场：按给药途径的估计和趋势分析

  • 给药途径：分段仪表板
  • 半固态剂型 CDMO 市场：依给药途径进行的变化分析
  • 依给药途径分类（2018-2030 年）
  • 外用药物
    • 局部製剂：半固态製剂 CDMO 市场（2018-2030 年）
  • 经皮吸收剂
    • 经皮药：半固态药物 CDMO 市场（2018-2030 年）
  • 其他的
    • 其他半固态剂型 CDMO 市场（2018-2030 年）

第 5 章半固态剂型 CDMO 市场：按产品分類的估计和趋势分析

  • 产品：细分仪表板
  • 半固态剂型 CDMO 市场：依产品进行差异分析
  • 按产品（2018 - 2030 年）
  • 软膏
    • 软膏：半固态剂型 CDMO 市场（2018-2030 年）
  • 乳霜和乳液
    • 乳霜与乳液：半固态剂型 CDMO 市场（2018-2030 年）
  • 贴上
    • 糊剂：半固态剂型 CDMO 市场（2018-2030 年）
  • 凝胶
    • 凝胶：半固态剂型 CDMO 市场（2018-2030 年）
  • 其他的
    • 其他：半固态剂型 CDMO 市场（2018-2030 年）

第 6 章半固态剂型 CDMO 市场：按服务分類的估计和趋势分析

  • 服务：细分仪表板
  • 半固态剂型 CDMO 市场：依服务进行差异分析
  • 依服务分类（2018-2030 年）
  • 合约开发
    • 合约开发：半固态剂型 CDMO 市场（2018-2030 年）
  • 契约製造
    • 契约製造：半固态剂量 CDMO 市场（2018-2030 年）

7. 半固态剂型 CDMO 市场：以最终用途进行的估计和趋势分析

  • 最终用途：分段式仪表板
  • 半固态剂型 CDMO 市场：依最终用途进行差异分析
  • 依最终用途分类（2018-2030 年）
  • 製药公司
    • 製药公司：半固态剂型 CDMO 市场（2018-2030 年）
  • 生物製药公司
    • 生物製药公司：半固态剂型 CDMO 市场（2018-2030 年）
  • 其他的
    • 其他：半固态剂型 CDMO 市场（2018-2030 年）

8. 半固态剂型 CDMO 市场：按地区分類的估计和趋势分析

  • 各地区市场占有率分析（2024 年及 2030 年）
  • 市场仪表板：按地区
  • 全球市场概况：按地区
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 瑞典
    • 丹麦
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 泰国
    • 韩国
    • 澳洲
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第九章 竞争格局

  • 公司分类
  • 各公司市场占有率分析（2024 年）
  • 公司简介
    • The Lubrizol Corporation
    • Cambrex Corporation
    • Contract Pharmaceuticals Limited.
    • Bora Pharmaceutical
    • Ascendia Pharmaceuticals
    • Pierre Fabre group
    • Piramal Pharma Solutions
    • DPT Laboratories, LTD
    • LGM Pharma
    • Pace Analytical Life Sciences, LLC.
Product Code: GVR-4-68040-477-4

Semi-Solid Dosage CDMO Market Growth & Trends:

The global semi-solid dosage CDMO market size is estimated to reach USD 67.40 billion by 2030, expanding at a CAGR of 11.90% from 2025 to 2030, according to a new report by Grand View Research, Inc. The global semi-solid dosage CDMO market size is driven due to growing trend towards personalized medicine coupled with increasing demand for innovative drug delivery systems. Patients prefer semi-solid formulations, such as creams, gels, and ointments, due to their ease of application and rapid absorption. Moreover, it has significant adoption for dermatological treatments to enhance patient treatment options. According to the data published by the American Academy of Dermatology Association in September 2024, Acne is the most common condition affecting approximately 50 million people in the U.S. annually. Moreover, 85% of the people are among age 12 to 24. Thus, increasing prevalence of skin disorders has led to an increasing demand for the development of topical formulations, consequently driving the demand for CDMOs to expand their capabilities in semi-solid dosage forms.

Furthermore, constant technological advancements in formulation and manufacturing processes have also propelled the semi-solid dosage market. Innovations such as nanotechnology and advanced emulsion techniques have improved the efficacy and stability of semi-solid formulations. These advancements enable CDMOs to produce high-quality products that meet stringent regulatory requirements, thereby attracting more clients. For instance, the development of nano-emulsions has enhanced the bioavailability of active ingredients, making semi-solid formulations more effective in treating various conditions, including chronic pain and inflammatory diseases.

In addition, increasing prevalence of chronic diseases, coupled with an aging population, is also contributing to the growth of the semi-solid dosage CDMO market. As more individuals seek treatments for conditions such as arthritis, diabetes, and skin disorders, the demand for effective semi-solid formulations is projected to increase in the coming years. This trend is particularly prominent in geriatric care, where semi-solid forms are often preferred due to their ease of use. Thus, these factors are further contributing to the market growth.

Semi-Solid Dosage CDMO Market Report Highlights:

  • Based on product, topical segment dominated in the market with a share of 88.53% in 2024. These formulations are particularly effective for localized treatments, making them ideal for dermatological applications
  • Based on rout of administration, the creams and lotions segment dominated the semi-solid dosage CDMO industry with 42.49% share in 2024. These formulations offer unique benefits such as ease of application, pleasant texture, and enhanced skin absorption which is contributing to the segment's growth
  • Based on service, the contract manufacturing segment accounted for the largest revenue share in 2024. Pharmaceutical companies are increasingly outsourcing their manufacturing processes to CDMOs to focus on core competencies such as research and development
  • Based on end use, the pharmaceutical companies segment accounted for the largest revenue share in 2024 owing to the increasing demand for innovative therapeutic solutions which has resulted into the increasing investment by the companies for the development of new drugs
  • North America dominated the market with a share of 41.37% in 2024. The increasing prevalence of chronic diseases and increasing demand for advanced therapeutic solutions in the region are propelling market expansion

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Route of Administration
    • 1.2.2. Product
    • 1.2.3. Service
    • 1.2.4. End Use
  • 1.3. Regional Scope
  • 1.4. Estimates And Forecast Timeline
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information Or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
    • 1.9.2. Parent Market Analysis
  • 1.10. List Of Secondary Sources
  • 1.11. List Of Abbreviations
  • 1.12. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Semi-Solid Dosage CDMO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Semi-Solid Dosage CDMO Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Semi-Solid Dosage CDMO Market: Route of Administration Estimates & Trend Analysis

  • 4.1. Route of Administration: Segment Dashboard
  • 4.2. Semi-Solid Dosage CDMO Market, By Route of Administration: Movement Analysis
  • 4.3. Semi-Solid Dosage CDMO Market Estimates & Forecasts, By Route of Administration, 2018 - 2030
  • 4.4. Topical
    • 4.4.1. Topical Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
  • 4.5. Transdermal
    • 4.5.1. Transdermal Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
  • 4.6. Others
    • 4.6.1. Others Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)

Chapter 5. Semi-Solid Dosage CDMO Market: Product Estimates & Trend Analysis

  • 5.1. Product: Segment Dashboard
  • 5.2. Semi-Solid Dosage CDMO Market, By Product: Movement Analysis
  • 5.3. Semi-Solid Dosage CDMO Market Estimates & Forecasts, By Product, 2018 - 2030
  • 5.4. Ointments
    • 5.4.1. Ointments Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
  • 5.5. Creams and Lotions
    • 5.5.1. Creams and Lotions Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
  • 5.6. Pastes
    • 5.6.1. Pastes Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
  • 5.7. Gels
    • 5.7.1. Gels Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
  • 5.8. Others
    • 5.8.1. Others Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)

Chapter 6. Semi-Solid Dosage CDMO Market: Service Estimates & Trend Analysis

  • 6.1. Service: Segment Dashboard
  • 6.2. Semi-Solid Dosage CDMO Market, By Service: Movement Analysis
  • 6.3. Semi-Solid Dosage CDMO Market Estimates & Forecasts, By Service, 2018 - 2030
  • 6.4. Contract Development
    • 6.4.1. Contract Development Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
  • 6.5. Contract Manufacturing
    • 6.5.1. Contract Manufacturing Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)

Chapter 7. Semi-Solid Dosage CDMO Market: End Use Estimates & Trend Analysis

  • 7.1. End Use: Segment Dashboard
  • 7.2. Semi-Solid Dosage CDMO Market, By End Use: Movement Analysis
  • 7.3. Semi-Solid Dosage CDMO Market Estimates & Forecasts, By End Use, 2018 - 2030
  • 7.4. Pharmaceutical Companies
    • 7.4.1. Pharmaceutical Companies Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
  • 7.5. Biopharmaceutical Companies
    • 7.5.1. Biopharmaceutical Companies Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
  • 7.6. Others
    • 7.6.1. Others Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)

Chapter 8. Semi-Solid Dosage CDMO Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2024 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. North America
    • 8.4.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Competitive Scenario
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Competitive Scenario
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Canada Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Competitive Scenario
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Mexico Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
  • 8.5. Europe
    • 8.5.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Competitive Scenario
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. UK Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Competitive Scenario
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Germany Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Competitive Scenario
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. France Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Competitive Scenario
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Italy Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Competitive Scenario
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Spain Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.5.7. Sweden
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Competitive Scenario
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. Sweden Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.5.8. Denmark
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Competitive Scenario
      • 8.5.8.3. Regulatory Framework
      • 8.5.8.4. Denmark Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.5.9. Norway
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Competitive Scenario
      • 8.5.9.3. Regulatory Framework
      • 8.5.9.4. Norway Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
  • 8.6. Asia Pacific
    • 8.6.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Competitive Scenario
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Japan Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Competitive Scenario
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. China Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Competitive Scenario
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. India Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.6.5. Thailand
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Competitive Scenario
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Thailand Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.6.6. South Korea
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Competitive Scenario
      • 8.6.6.3. Regulatory Framework
      • 8.6.6.4. South Korea Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.6.7. Australia
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Competitive Scenario
      • 8.6.7.3. Regulatory Framework
      • 8.6.7.4. Australia Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
  • 8.7. Latin America
    • 8.7.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Competitive Scenario
      • 8.7.2.3. Regulatory Framework
      • 8.7.2.4. Brazil Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Competitive Scenario
      • 8.7.3.3. Regulatory Framework
      • 8.7.3.4. Argentina Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
  • 8.8. MEA
    • 8.8.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Competitive Scenario
      • 8.8.2.3. Regulatory Framework
      • 8.8.2.4. South Africa Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Competitive Scenario
      • 8.8.3.3. Regulatory Framework
      • 8.8.3.4. Saudi Arabia Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Competitive Scenario
      • 8.8.4.3. Regulatory Framework
      • 8.8.4.4. UAE Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Competitive Scenario
      • 8.8.5.3. Regulatory Framework
      • 8.8.5.4. Kuwait Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization
  • 9.2. Company Market Share Analysis, 2024
  • 9.3. Company Profiles
    • 9.3.1. The Lubrizol Corporation
      • 9.3.1.1. Company Overview
      • 9.3.1.2. Financial Performance
      • 9.3.1.3. Service Benchmarking
      • 9.3.1.4. Strategic Initiatives
    • 9.3.2. Cambrex Corporation
      • 9.3.2.1. Company Overview
      • 9.3.2.2. Financial Performance
      • 9.3.2.3. Service Benchmarking
      • 9.3.2.4. Strategic Initiatives
    • 9.3.3. Contract Pharmaceuticals Limited.
      • 9.3.3.1. Company Overview
      • 9.3.3.2. Financial Performance
      • 9.3.3.3. Service Benchmarking
      • 9.3.3.4. Strategic Initiatives
    • 9.3.4. Bora Pharmaceutical
      • 9.3.4.1. Company Overview
      • 9.3.4.2. Financial Performance
      • 9.3.4.3. Service Benchmarking
      • 9.3.4.4. Strategic Initiatives
    • 9.3.5. Ascendia Pharmaceuticals
      • 9.3.5.1. Company Overview
      • 9.3.5.2. Financial Performance
      • 9.3.5.3. Service Benchmarking
      • 9.3.5.4. Strategic Initiatives
    • 9.3.6. Pierre Fabre group
      • 9.3.6.1. Company Overview
      • 9.3.6.2. Financial Performance
      • 9.3.6.3. Service Benchmarking
      • 9.3.6.4. Strategic Initiatives
    • 9.3.7. Piramal Pharma Solutions
      • 9.3.7.1. Company Overview
      • 9.3.7.2. Financial Performance
      • 9.3.7.3. Service Benchmarking
      • 9.3.7.4. Strategic Initiatives
    • 9.3.8. DPT Laboratories, LTD
      • 9.3.8.1. Company Overview
      • 9.3.8.2. Financial Performance
      • 9.3.8.3. Service Benchmarking
      • 9.3.8.4. Strategic Initiatives
    • 9.3.9. LGM Pharma
      • 9.3.9.1. Company Overview
      • 9.3.9.2. Financial Performance
      • 9.3.9.3. Service Benchmarking
      • 9.3.9.4. Strategic Initiatives
    • 9.3.10. Pace Analytical Life Sciences, LLC.
      • 9.3.10.1. Company Overview
      • 9.3.10.2. Financial Performance
      • 9.3.10.3. Service Benchmarking
      • 9.3.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 4 Global Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 5 Global Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 6 Global Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 7 Global Semi-Solid Dosage CDMO, by Region, 2018 - 2030 (USD Million)
  • Table 8 North America Semi-Solid Dosage CDMO, by Country, 2018 - 2030 (USD Million)
  • Table 9 North America Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 10 North America Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 11 North America Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 12 North America Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 13 U.S. Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 14 U.S. Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 15 U.S. Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 16 U.S. Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 17 Canada Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 18 Canada Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 19 Canada Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 20 Canada Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 21 Mexico Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 22 Mexico Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 23 Mexico Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 24 Mexico Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 25 Europe Semi-Solid Dosage CDMO, by Country, 2018 - 2030 (USD Million)
  • Table 26 Europe Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 27 Europe Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 28 Europe Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 29 Europe Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 30 UK Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 31 UK Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 32 UK Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 33 UK Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 34 Germany Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 35 Germany Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 36 Germany Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 37 Germany Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 38 France Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 39 France Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 40 France Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 41 France Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 42 Italy Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 43 Italy Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 44 Italy Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 45 Italy Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 46 Spain Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 47 Spain Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 48 Spain Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 49 Spain Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 50 Denmark Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 51 Denmark Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 52 Denmark Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 53 Denmark Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 54 Sweden Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 55 Sweden Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 56 Sweden Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 57 Sweden Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 58 Norway Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 59 Norway Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 60 Norway Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 61 Norway Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 62 Asia Pacific Semi-Solid Dosage CDMO, by Country, 2018 - 2030 (USD Million)
  • Table 63 Asia Pacific Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 64 Asia Pacific Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 65 Asia Pacific Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 66 Asia Pacific Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 67 Japan Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 68 Japan Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 69 Japan Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 70 Japan Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 71 China Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 72 China Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 73 China Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 74 China Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 75 India Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 76 India Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 77 India Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 78 India Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 79 Thailand Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 80 Thailand Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 81 Thailand Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 82 Thailand Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 83 South Korea Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 84 South Korea Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 85 South Korea Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 86 South Korea Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 87 Australia Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 88 Australia Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 89 Australia Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 90 Australia Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 91 Latin America Semi-Solid Dosage CDMO, by Country, 2018 - 2030 (USD Million)
  • Table 92 Latin America Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 93 Latin America Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 94 Latin America Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 95 Latin America Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 96 Brazil Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 97 Brazil Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 98 Brazil Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 99 Brazil Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 100 Argentina Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 101 Argentina Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 102 Argentina Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 103 Argentina Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 104 Middle East & Africa Semi-Solid Dosage CDMO, by Country, 2018 - 2030 (USD Million)
  • Table 105 Middle East & Africa Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 106 Middle East & Africa Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 107 Middle East & Africa Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 108 Middle East & Africa Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 109 South Africa Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 110 South Africa Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 111 South Africa Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 112 South Africa Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 113 Saudi Arabia Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 114 Saudi Arabia Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 115 Saudi Arabia Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 116 Saudi Arabia Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 117 UAE Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 118 UAE Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 119 UAE Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 120 UAE Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 121 Kuwait Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 122 Kuwait Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 123 Kuwait Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 124 Kuwait Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modelling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Semi-Solid Dosage CDMO Market revenue, 2018 - 2030 (USD Million)
  • Fig. 10 Semi-Solid Dosage CDMO Market snapshot
  • Fig. 11 Semi-Solid Dosage CDMO Market driver impact
  • Fig. 12 Semi-Solid Dosage CDMO Market restraint impact
  • Fig. 13 Semi-Solid Dosage CDMO sector Route of administration takeaways (USD Million)
  • Fig. 14 Semi-Solid Dosage CDMO Market: Route of administration movement analysis
  • Fig. 15 Topical market, 2018 - 2030 (USD Million)
  • Fig. 16 Transdermal market, 2018 - 2030 (USD Million)
  • Fig. 17 Others market, 2018 - 2030 (USD Million)
  • Fig. 18 Semi-Solid Dosage CDMO sector Product takeaways (USD Million)
  • Fig. 19 Semi-Solid Dosage CDMO Market: Product movement analysis
  • Fig. 20 Ointments market, 2018 - 2030 (USD Million)
  • Fig. 21 Creams and Lotions market, 2018 - 2030 (USD Million)
  • Fig. 22 Pastes market, 2018 - 2030 (USD Million)
  • Fig. 23 Gels market, 2018 - 2030 (USD Million)
  • Fig. 24 Others market, 2018 - 2030 (USD Million)
  • Fig. 25 Semi-Solid Dosage CDMO sector Service takeaways (USD Million)
  • Fig. 26 Semi-Solid Dosage CDMO Market: Service movement analysis
  • Fig. 27 Contract Development market, 2018 - 2030 (USD Million)
  • Fig. 28 Contract Manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 29 Semi-Solid Dosage CDMO sector End Use takeaways (USD Million)
  • Fig. 30 Semi-Solid Dosage CDMO Market: End Use movement analysis
  • Fig. 31 Pharmaceutical Companies market, 2018 - 2030 (USD Million)
  • Fig. 32 Biopharmaceutical Companies market, 2018 - 2030 (USD Million)
  • Fig. 33 Others market, 2018 - 2030 (USD Million)
  • Fig. 34 Regional marketplace: Key takeaways
  • Fig. 35 Regional outlook, 2024 & 2030
  • Fig. 36 North America Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 37 U.S. Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 38 Canada Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 39 Mexico Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 40 Europe Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 41 UK Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 42 Germany Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 43 France Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 44 Italy Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 45 Spain companion animal Health market, 2018 - 2030 (USD Million)
  • Fig. 46 Sweden Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 47 Denmark Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 48 Norway Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 49 Asia Pacific Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 50 Japan Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 51 China Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 52 India Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 53 Thailand Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 54 South Korea Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 55 Australia Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 56 Latin America Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 57 Brazil Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 58 Argentina Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 59 Middle East & Africa Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 60 South Africa Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 61 Saudi Arabia Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 62 UAE Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 63 Kuwait Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 64 Market participant categorization